Sun Pharm acquires rights to trademarks of 3 diabetes drug brands in India from AstraZeneca

28 May 2021 Evaluate

Sun Pharma has acquired the rights to trademarks of diabetes drug Dapagliflozin under brands Oxra, Oxramet and Oxraduo in India from AstraZeneca AB, Sweden, parent company of AstraZeneca Pharma India with effect from May 28, 2021. The company has also taken a patent license to manufacture and commercialise Dapagliflozin and Dapagliflozin with Metformin combination in India from AstraZeneca AB with effect from May 28, 2021.

Consequently, AstraZeneca India and Sun Pharma have discontinued their existing distribution services agreement signed in 2016, for distribution of Dapagliflozin.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1786.05 -40.05 (-2.19%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.